Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neuroscience -- Ignore unavailable to you. Want to Upgrade?

To: Jim Oravetz who wrote (143)	12/4/2000 4:11:12 AM
From: nigel bates	Respond to of 278

Message 14937596

To: Jim Oravetz who wrote (143)	12/19/2000 12:37:32 PM
From: Jim Oravetz	Read Replies (1) \| Respond to of 278

Axonyx Starts Phase II Trial On Potential Alzheimer's Drug Dow Jones Newswires NEW YORK -- Axonyx Inc. (AXYX) started a Phase II clinical trial for Phenserine, its lead drug candidate for the treatment of Alzheimer's disease. In a press release Tuesday, Axonyx said the trial is an important step toward obtaining approval to market the drug. The Phase II study is double blind and designed to determine the efficacy and safety in patients with the clinical signs of mild to moderate Alzheimer's disease. The first patients have been randomized and will receive either active or placebo treatment. The study is being conducted in the U.S. at two clinical sites. Study results are expected toward the end of the second quarter. In September, Axonyx said a multiple dose Phase I trial of Phenserine demonstrated that the Alzheimer's drug is safe, well-tolerated and inhibits red blood cell enzyme acetylcholinesterase. Company Web site: axonyx.com